Obesity and its nurturing effect on hepatitis C

Hepatology

Volumn 38, Issue 3, 2003, Pages 557-559

  McCullough, Arthur J ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Ohio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

BODY FAT; BODY MASS; CHRONIC HEPATITIS; DISEASE ASSOCIATION; EDITORIAL; ERADICATION THERAPY; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LIVER BIOPSY; LIVER CIRRHOSIS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; TISSUE DISTRIBUTION;

EID: 0042322996     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50413     Document Type: Article

References (16)

1. Adinolfi LE, Gambardella M, Adreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001;33:1358-1364.
2. Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J. Contribution of obesity to Hepatitis C related fibrosis progression. Am J Gastroenterol 2002;97:2408-2414.
3. Hourigan LF, MacDonald GA, Purie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic Hepatitis C correlates significantly body mass index and steatosis. HEPATOLOGY 1999;29:1215-1219.
4. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic Hepatitis C. J Hepatol 2001;34:730-739.
5. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic Hepatitis C. HEPATOLOGY 2003;38:639-644.
6. McCullough AJ, Falck-Ytter Y. Body composition and hepatic steatosis as precursors for fibrotic disease. HEPATOLOGY 1999;29:1328-1330.
7. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JE, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1999;34:1714-1717.
8. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, et al. Peg interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343;1666-1672.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, et al. Peg interferon alfa-a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
10. Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmakinetics and biologic effect of interferon-α in hepatitis C. Dig Dis Sci 1997;42:178-185.
11. Banerjee D, Williams EV, Ilorr J, Monypenny IJ, Webster DJT. Obesity predisposes to increased drainage following axillary node clearance: a prospective audit. Ann R Coli Surg Engl 2001;83:268-271.
12. Porter CJH, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 2000;89:297-310.
13. Taliani G, Duca F, Lecce R, Livoli D, Pasquazzi C, DeBac C. Hepatic liodocaine metabolism in chronic hepatitis C virus hepatitis with or without steatosis. HEPATOLOGY 1995;21:1760-1761.
14. Marti A, Marcos A, Martinez JA. Obesity and immune function relationships. Obesity Reviews 2001;2:131-140.
15. Masaki N, Fukushima S, Hayashi S. Lower Th-1/TH-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig Dis Sci 2002;47:2163-2169.
16. Hickman JJ, Clouston AD, MacDonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.